Transthyretin cardiac amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: a single center experience. (3rd October 2022)
- Record Type:
- Journal Article
- Title:
- Transthyretin cardiac amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: a single center experience. (3rd October 2022)
- Main Title:
- Transthyretin cardiac amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: a single center experience
- Authors:
- Scudeler, L
Gallone, G
Bongiovanni, C
Bruno, F
Landra, F
Andreis, A
Fava, A
Pidello, S
Raineri, C
Giorgi, M
D'Ascenzo, F
Conrotto, F
Alunni, G
Rinaldi, M
De Ferrari, G M - Abstract:
- Abstract: Background: Even if prevalent among patients with severe aortic stenosis (AS), the clinical suspicion for transthyretin cardiac amyloidosis (ATTR-CA) remains difficult in this subset. Methods: Consecutive severe AS patients undergoing transcatheter aortic valve replacement (TAVR) evaluation at a single center were prospectively included. Those with suspected ATTR-CA based on clinical assessment underwent 99mTc-DPD cardiac scintigraphy. The RAISE score, a novel screening tool with high sensitivity for ATTR-CA in AS, was retrospectively calculated to rule-out ATTR-CA in the remaining patients. Patients were categorized as follow: "ATTR-CA+": patients with confirmed ATTR-CA at 99mTc-DPD cardiac scintigraphy; "ATTR-CA−": patients with negative 99mTc-DPD cardiac scintigraphy or a negative RAISE score; c) "ATTR-CA indeterminate": patients not undergoing ATTR-CA assessment with a positive RAISE score. The characteristics of ATTR-CA+ and ATTR-CA− patients were compared. Results: Of 107 included patients, ATTR-CA suspicion was posed in 13 patients and confirmed in 6. Patients were categorized as follow: 6 (5.6%) ATTR-CA+, 79 (73.8%) ATTR-CA−, 22 (20.6%) ATTR-CA indeterminate. Excluding ATTR-CA indeterminate patients, the prevalence of ATTR-CA was 7.1%. As compared to ATTR-CA− patients, ATTR-CA+ patients were older, had higher procedural risk and more extensive myocardial and renal damage. They had higher left ventricle mass index and lower ECG voltages, translating into aAbstract: Background: Even if prevalent among patients with severe aortic stenosis (AS), the clinical suspicion for transthyretin cardiac amyloidosis (ATTR-CA) remains difficult in this subset. Methods: Consecutive severe AS patients undergoing transcatheter aortic valve replacement (TAVR) evaluation at a single center were prospectively included. Those with suspected ATTR-CA based on clinical assessment underwent 99mTc-DPD cardiac scintigraphy. The RAISE score, a novel screening tool with high sensitivity for ATTR-CA in AS, was retrospectively calculated to rule-out ATTR-CA in the remaining patients. Patients were categorized as follow: "ATTR-CA+": patients with confirmed ATTR-CA at 99mTc-DPD cardiac scintigraphy; "ATTR-CA−": patients with negative 99mTc-DPD cardiac scintigraphy or a negative RAISE score; c) "ATTR-CA indeterminate": patients not undergoing ATTR-CA assessment with a positive RAISE score. The characteristics of ATTR-CA+ and ATTR-CA− patients were compared. Results: Of 107 included patients, ATTR-CA suspicion was posed in 13 patients and confirmed in 6. Patients were categorized as follow: 6 (5.6%) ATTR-CA+, 79 (73.8%) ATTR-CA−, 22 (20.6%) ATTR-CA indeterminate. Excluding ATTR-CA indeterminate patients, the prevalence of ATTR-CA was 7.1%. As compared to ATTR-CA− patients, ATTR-CA+ patients were older, had higher procedural risk and more extensive myocardial and renal damage. They had higher left ventricle mass index and lower ECG voltages, translating into a lower voltage to mass ratio. Moreover, bifascicular block was more common. No difference in procedural outcomes and 1-year mortality was observed between groups. Conclusions: Among severe AS patients, ATTR-CA is prevalent and presents with phenotypic features that may aid to differentiate it from lone AS. A clinical approach based on routine search of amyloidosis features may effectively lead to selective 99mTc-DPD cardiac scintigraphy with a satisfactory positive predictive value. Funding Acknowledgement: Type of funding sources: None. … (more)
- Is Part Of:
- European heart journal. Volume 43(2022)Supplement 2
- Journal:
- European heart journal
- Issue:
- Volume 43(2022)Supplement 2
- Issue Display:
- Volume 43, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 43
- Issue:
- 2
- Issue Sort Value:
- 2022-0043-0002-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-10-03
- Subjects:
- Cardiology -- Periodicals
Heart -- Diseases -- Periodicals
616.12005 - Journal URLs:
- http://eurheartj.oxfordjournals.org/ ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/eurheartj/ehac544.1794 ↗
- Languages:
- English
- ISSNs:
- 0195-668X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.717500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24441.xml